• 34889 Citations
  • 86 h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 41 Similar Profiles
Major Depressive Disorder Medicine & Life Sciences
Depression Medicine & Life Sciences
Antidepressive Agents Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Outpatients Medicine & Life Sciences
Citalopram Medicine & Life Sciences
Psychiatry Medicine & Life Sciences
Self Report Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results

Thase, M., Stanford, A. D., Memisoglu, A., Martin, W., Claxton, A., Bodnik, J. A., Trivedi, M. H., Fava, M. & Pathak, S., Feb 1 2019, In : CNS spectrums. 24, 1, p. 203-204 2 p.

Research output: Contribution to journalArticle

Open Access
Major Depressive Disorder
Antidepressive Agents

Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control

Liao, A., Walker, N. R., Carmody, T. J., Cooper Cortes, C., Shaw, M. A., Grannemann, B. D., Adams, P., Bruder, G. E., McInnis, M. G., Webb, C. A., Dillon, D. G., Pizzagalli, D. A., Phillips, M. L., Kurian, B. T., Fava, M., Parsey, R. V., McGrath, P. J., Weissman, M. M. & Trivedi, M. H., Feb 15 2019, In : Journal of Affective Disorders. 245, p. 1070-1078 9 p.

Research output: Contribution to journalArticle

Major Depressive Disorder

Can targeted metabolomics predict depression recovery? Results from the CO-MED trial

Czysz, A. H., South, C., Gadad, B., Arning, E., Soyombo, A., Bottiglieri, T. & Trivedi, M. H., Dec 1 2019, In : Translational Psychiatry. 9, 1, 11.

Research output: Contribution to journalArticle


Correction to: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (Molecular Psychiatry, (2018), 10.1038/s41380-018-0256-5)

Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrough, J., Debattista, C., Schatzberg, A. F., Trivedi, M. H., Jha, M. K., Sanacora, G., Wilkinson, S. T. & Papakostas, G. I., Jan 1 2019, (Accepted/In press) In : Molecular Psychiatry.

Research output: Contribution to journalArticle

Treatment-Resistant Depressive Disorder

Definition of treatment-resistant depression – Asia Pacific perspectives

Ng, C. H., Kato, T., Han, C., Wang, G., Trivedi, M. H., Ramesh, V., Shao, D., Gala, S., Narayanan, S., Tan, W., Feng, Y. & Kasper, S., Feb 15 2019, In : Journal of Affective Disorders. 245, p. 626-636 11 p.

Research output: Contribution to journalReview article

Treatment-Resistant Depressive Disorder
Antidepressive Agents
Quality of Life